Therefore, targeting the expression or functional modulation of TPM2, PDLIM7, or YAP1 may serve as a promising therapeutic strategy to reduce PCa proliferation and prevent the progression of CRPC. Here, PDLIM7 is linked to posterior cortical atrophy.